Crossmark

Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage

Crossref DOI link: https://doi.org/10.1007/s11239-021-02495-3

Published Online: 2021-06-08

Published Print: 2022-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vestal, Mark L. https://orcid.org/0000-0002-8650-2815
Hodulik, Kimberly

Mando-Vandrick, Jennifer

James, Michael L.

Ortel, Thomas L.

Fuller, Matthew

Notini, Maria

Friedland, Mark

Welsby, Ian J.
License Information

Text and Data Mining valid from 2021-06-08

Version of Record valid from 2021-06-08
More Information

Article History

Accepted: 29 May 2021

First Online: 8 June 2021

Declarations

:

: MLV, KH, JMV, M. Fuller, MN, M. Friedland, and IW have no relevant conflicts of interests to disclose. MLJ has received research funding from Bard, AegisCN, and NICO Corporation. TLO has received research grants from Instrumentation Laboratory, Stago, and Siemens, and has received consulting fees from Instrumentation Laboratory.

: IRB-approved.

Document is current

Any future updates will be listed below